These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3954966)

  • 1. Complete remission in plasma cell leukaemia.
    Montecucco C; Riccardi A; Merlini G; Ascari E
    Br J Haematol; 1986 Mar; 62(3):525-7. PubMed ID: 3954966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remission in plasma cell leukaemia.
    Krsnik I; Peñalver MA; Del Potro E; Diaz-Mediavilla J
    Br J Haematol; 1987 May; 66(1):145. PubMed ID: 3593651
    [No Abstract]   [Full Text] [Related]  

  • 3. [Complete double remission and prolonged survival of a patient diagnosed with plasma cell leukemia].
    Sureda A; Pérez de Oteyza J; García Laraña J; Odriozola J
    Sangre (Barc); 1989 Jun; 34(3):244. PubMed ID: 2762986
    [No Abstract]   [Full Text] [Related]  

  • 4. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
    Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
    Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective cytotoxic treatment of primary plasma cell leukaemia--a report of 3 cases.
    Gangadharan VP; Satishkumar K; Pillai R; Cherian V
    Acta Oncol; 1994; 33(6):714-5. PubMed ID: 7946458
    [No Abstract]   [Full Text] [Related]  

  • 6. [Case of plasmacytic leukemia with complete remission and 1-year survival after a combined 5-drug sequence therapy].
    Anisimowicz J; Mizan K
    Pol Tyg Lek; 1984 Sep; 39(36):1209-10. PubMed ID: 6504747
    [No Abstract]   [Full Text] [Related]  

  • 7. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
    Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.
    Merlini G; Riccardi A; Riccardi PG; Montecucco CM; Pavesi F; Ascari E
    Tumori; 1985 Dec; 71(6):581-8. PubMed ID: 4082291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy].
    Shindo T; Yumoto Y; Yoshida M; Okuda T
    Rinsho Ketsueki; 2002 Feb; 43(2):107-11. PubMed ID: 11925872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha.
    Yamagata N; Shimazaki C; Goto H; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Nakagawa M
    Am J Hematol; 1994 Mar; 45(3):262-4. PubMed ID: 8296801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptichemio induction therapy in myelomatosis.
    Merlini G; Gobbi PG; Riccardi A; Riva G; Sardi C; Perugini S
    Cancer Chemother Pharmacol; 1982; 8(1):9-16. PubMed ID: 7094202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    Libby E; Candelaria-Quintana D; Moualla H; Abdul-Jaleel M; Rabinowitz I
    Am J Hematol; 2010 Sep; 85(9):733-4. PubMed ID: 20669178
    [No Abstract]   [Full Text] [Related]  

  • 14. [Results with the use of the M-2 protocol in plasmacytoma].
    Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
    Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary plasma cell leukaemia. A case report and a review of the literature.
    Osanto S; Müller HP; Schuit HR; Van Nieuwkoop JA; Willemze R
    Acta Haematol; 1983; 70(2):122-9. PubMed ID: 6408874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone.
    Walker JD; Kaczmarski RS
    Postgrad Med J; 1988 Mar; 64(749):232-5. PubMed ID: 3174543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell leukemia--report on two cases.
    Singh VP; Sundar S; Kumar K; Shukla J; Dube B
    J Assoc Physicians India; 1994 Oct; 42(10):824-5. PubMed ID: 7876056
    [No Abstract]   [Full Text] [Related]  

  • 18. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [p170 in multiple myeloma and acute leukemia].
    Riccardi A; Invernizzi R; Ucci G; Luoni R; Danova M; Giordano M; Zambelli ML; Rastaldi MP; Ascari E
    Haematologica; 1991 Jun; 76 Suppl 3():177-80. PubMed ID: 1684345
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.